Presentation Date
13-10-2022 12:00 AM
Description
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant B.1.1.529 and subvariant BA.2 were first detected in late 2021. The Omicron variant quickly became the most widespread in the United States due to its increased transmissibility compared to previous SARS-CoV-2 variants. The BA.2 sub-lineage has been shown to be particularly communicable and was the most prevalent strain in the United States as of March 2022. It is unknown if this increased infectivity of BA.2 is due to depressed antibody quantities following vaccination against wild-type virus or previous infection with other strains of SARSCoV-2. The goal of this study is to determine antibody titers against the receptor binding domain (RBD) of strains B.1.1.529 and BA.2 following vaccination and/or infection with the virus and compare this data to that of the wild-type strain. METHODS: Subjects were enrolled in a natural history study of the immune response to COVID-19 infection. Informed consent was obtained, and 10 ml of blood was collected and tested for antibodies against COVID-19 proteins. Subjects were followed at 6-month intervals or after vaccination. RBD antigen for either the B.1.1.529 and BA.2 strain were coated on 96 well Immulon-2 plates overnight at 4°C. The plates were washed with PBS, blocked, 2-fold dilutions of serum were added to the antigen coated plates and incubated at room temperature for 2 hours. The plates were washed and then coated with goat anti-human IgG linked to alkaline phosphatase for another 2 hours, developed, and read at 405nm absorbance. End-point dilution titers were determined and compared between wild type (WT, previously done), B.1.1.529 and BA.2 strains. RESULTS: A subset of 23 subjects were more closely examined after initial vaccination and follow-up boosting (2nd dose) comprising a total of 60 samples. The overall rate of seropositivity was 91.3%, 69.0%, and 74.1% for the WT, B.1.1.529, and BA.2 strains respectively. In the prevaccine samples, the WT titers were significantly higher compared to titers against the other 2 strains (p
Recommended Citation
Tate, Brendan; Trauth, Amber; Ramsay, Alistair; and Hagensee, Michael, "Antibody titers against SARS-CoV-2 Omicron variant B.1.1.529 and subvariant BA.2 following vaccination" (2022). Medical Research Day. 102.
https://digitalscholar.lsuhsc.edu/sommrd/2022MRD/Posters/102
Included in
Antibody titers against SARS-CoV-2 Omicron variant B.1.1.529 and subvariant BA.2 following vaccination
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant B.1.1.529 and subvariant BA.2 were first detected in late 2021. The Omicron variant quickly became the most widespread in the United States due to its increased transmissibility compared to previous SARS-CoV-2 variants. The BA.2 sub-lineage has been shown to be particularly communicable and was the most prevalent strain in the United States as of March 2022. It is unknown if this increased infectivity of BA.2 is due to depressed antibody quantities following vaccination against wild-type virus or previous infection with other strains of SARSCoV-2. The goal of this study is to determine antibody titers against the receptor binding domain (RBD) of strains B.1.1.529 and BA.2 following vaccination and/or infection with the virus and compare this data to that of the wild-type strain. METHODS: Subjects were enrolled in a natural history study of the immune response to COVID-19 infection. Informed consent was obtained, and 10 ml of blood was collected and tested for antibodies against COVID-19 proteins. Subjects were followed at 6-month intervals or after vaccination. RBD antigen for either the B.1.1.529 and BA.2 strain were coated on 96 well Immulon-2 plates overnight at 4°C. The plates were washed with PBS, blocked, 2-fold dilutions of serum were added to the antigen coated plates and incubated at room temperature for 2 hours. The plates were washed and then coated with goat anti-human IgG linked to alkaline phosphatase for another 2 hours, developed, and read at 405nm absorbance. End-point dilution titers were determined and compared between wild type (WT, previously done), B.1.1.529 and BA.2 strains. RESULTS: A subset of 23 subjects were more closely examined after initial vaccination and follow-up boosting (2nd dose) comprising a total of 60 samples. The overall rate of seropositivity was 91.3%, 69.0%, and 74.1% for the WT, B.1.1.529, and BA.2 strains respectively. In the prevaccine samples, the WT titers were significantly higher compared to titers against the other 2 strains (p
Comments
IN COPYRIGHT. For more information about this rights statement, please visit http://rightsstatements.org/vocab/InC/1.0/